Patient-tailored azacitidine, venetoclax and gilteritinib triplet therapy appear to improve tolerability while preserving encouraging clinical outcomes in FLT3-mutated relapsed/refractory AML.
Overview & Synopsis
Open access biomedical research article published in Ann Hematol.
Indexed from repository: PubMed Central
(
pmc.ncbi.nlm.nih.gov)
Keyboard Shortcuts:
← / → for pages • + / - for zoom • 0 to fit width
Powered by Mozilla PDF.js v3.11
Document Information
| Document Title | Patient-tailored azacitidine, venetoclax and gilteritinib triplet therapy appear to improve tolerability while preserving encouraging clinical outcomes in FLT3-mutated relapsed/refractory AML. |
|---|---|
| Author / Organization | Arvidsson Kvissberg M, Nilsson C, Landberg N, Österroos A, Papageorgiou A, Uggla B, Lazarevic V, Deneberg S, Jädersten M |
| Subject & Discipline | Ann Hematol |
| Categories | Medicine & Health |
| Publication Year | 2026 |
| License / Rights | Open Access / Creative Commons |
| Resource Verification | Listed PDF (Verification Pending) |
| Original Host Website |
PubMed Central
(pmc.ncbi.nlm.nih.gov)
|
| File Format | application/pdf (Portable Document Format) |
| Language | EN |
| Catalog ID | DOC-12759 |
| Original Source Link | Visit Source Page on pmc.ncbi.nlm.nih.gov » |